Cell therapy developers moving from early research into clinical manufacturing face pressure to replace static culture systems with scalable, automation-ready platforms that meet cGMP requirements—often under tight timelines and space constraints.

The CTS DynaXS Single Use Bioreactor is a stirred-tank, single-use cell expansion platform designed to support that transition, covering process development through clinical and commercial manufacturing volumes. It integrates within the Gibco Cell Therapy Systems (CTS) portfolio, which spans cell isolation, activation, expansion, and downstream processing, with unified technical support and regulatory documentation across the workflow.

The system's flexible design supports a wide range of operating conditions, cell types, and production volumes, and is built with automation-ready architecture to reduce manual interventions and support reproducible performance as programs advance. The platform is intended to support cell therapy applications across oncology, autoimmune, and other emerging therapeutic indications.

Features:

• Stirred-tank, single-use design
• Scalable from small process development batches to larger cGMP manufacturing runs
• Automation-ready architecture
• Flexible operating parameters supporting multiple cell types and volumes
• Integrated within the CTS portfolio (cell isolation through downstream processing)
• Modular workflow design with unified technical support
• Streamlined regulatory documentation across development stages
• Designed to reduce manual interventions and scale-up variability

Thermo Fisher Scientific
Waltham, MA
(781) 622-1000
thermofisher.com